Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?
ABSTRACT Experimental evidence gathered from preclinical IBD models and conducted in rodents point to a strong potential of the ECS components to serve as drug targets in inflammatory diseases of the intestine. Data suggest a homeostatic role of the ECS in the gut. Accordingly, it is believed that the enhancement of endocannabinoid signaling, as observed …
Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go? Read More »